CCDC84 Inhibitors
CCDC84 inhibitors are chemical compounds that directly or indirectly inhibit the functional activity of CCDC84 through specific signaling pathways or biological processes. The mechanism of action for these inhibitors varies, depending on the cellular pathway involved. For instance, rapamycin, a well-known mTOR inhibitor, forms a complex with FKBP12 that binds and inhibits mTOR. Inhibition of mTOR can lead to diminished cell growth and proliferation, which may affect proteins like CCDC84 that are potentially regulated by mTOR signaling. Similarly, the PI3K inhibitors LY294002 and Wortmannin can lead to a reduction in AKT phosphorylation and subsequent mTOR signaling inhibition, which again may downregulate CCDC84 if its activity is linked to the PI3K/AKT/mTOR pathway.
On another front, MAPK pathway inhibitors such as U0126, SB203580, SP600125, PD98059, and Sorafenib target different kinases within the pathway. U0126 and PD98059 are specific MEK inhibitors, impeding ERK activation which can lead to the suppression of CCDC84 if it is downstream of the MAPK/ERK signaling. SB203580 and SP600125 inhibit p38 MAPK and JNK, respectively, which may reduce CCDC84 activity if it is modulated by stress-induced signaling pathways. Dasatinib, an Src kinase inhibitor, and Imatinib, a tyrosine kinase inhibitor, can inhibit various signal transduction pathways, potentially leading to the decreased activity of CCDC84 if it is regulated by tyrosine kinase signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, a kinase involved in cell growth and proliferation, which could impede CCDC84 if it is mTOR-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that curtails the PI3K/AKT pathway, leading to reduced cell survival and growth signals that can negatively affect CCDC84 if it is PI3K/AKT-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that interrupts the MAPK/ERK pathway, potentially diminishing CCDC84 activity if it is involved in this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor that can disrupt inflammatory responses and cellular stress pathways, possibly inhibiting CCDC84 if it relies on p38 MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that could suppress CCDC84 if it is activated by stress-induced JNK signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that can attenuate the PI3K/AKT/mTOR pathway, potentially reducing CCDC84 activity if it is regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor that can impede the MAPK/ERK pathway, potentially lowering CCDC84 activity if it is part of this signaling cascade. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is an Src kinase inhibitor that can hinder various signal transduction pathways, potentially inhibiting CCDC84 if it is involved in Src kinase-regulated pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, potentially inhibiting CCDC84 if it depends on proteasomal degradation for regulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF inhibitor that can interfere with the MAPK/ERK pathway, potentially inhibiting CCDC84 if it is regulated by RAF-mediated signaling. | ||||||